Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Medtronic PLC    MDT   IE00BTN1Y115

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Medtronic : J&J to close its Animas Corp. diabetes-care business in Chesterbrook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 03:37am CEST

Oct. 05--Animas Corp., a Johnson & Johnson diabetes-care company in Chesterbrook, said Thursday that it plans to close operations and get out of the insulin-pump business.

About 90,000 patients using Animas pumps will be offered the option of transferring to pumps made by Medtronic PLC, the company said.

Animas employs 410 globally, about half of whom work in Chesterbrook and at a manufacturing plant in West Chester.

In January, Johnson & Johnson said it was evaluating strategic options, including the possible sale of some of its diabetes-care businesses. J&J said Thursday that it continues to review potential options for its blood-glucose monitoring business, LifeScan Inc.

Animas will stop selling the pumps, Animas Vibe and OneTouch Ping, in the United States and Canada, effective immediately. Operations in other countries will continue for a while, but eventually end, the company said.

"We will continue to operate certain functions of the business -- including manufacturing, customer and safety support, as examples -- for an indeterminate amount of time as we help our patients transition," said Bridget Doherty, spokeswoman for Animas. "Accordingly, we will provide support to impacted employees and their families through the transition.

"A decision and timing to exit markets outside of the U.S. and Canada is pending consultation with relevant works councils," she said.

Chesterbrook and West Chester will continue to operate for an "indeterminate amount of time to provide support for our current patients, help them transition, and to support the business outside the U.S. and Canada," she said.

Valerie Asbury, general manager of Animas, said: "With changing needs of customers, rapidly evolving market dynamics, and increased competitive pressures, it proved too difficult to sustain the insulin-pump business, and we decided to pursue an exit. This decision was extremely difficult and comes following the extensive exploration of all other viable options for the Animas business."

Animas said it will work with Medtronic as a "partner of choice" to help ensure a smooth transition for patients on insulin pumps.

In a statement late Thursday, JDRF, formerly known as the Juvenile Diabetes Research Foundation, said the Animas closing takes away choice for 1.25 million Americans with type 1 diabetes. Animas is the second-largest manufacturer of insulin pumps, after No. 1 Medtronic.

"It means fewer treatment options," said Derek Rapp, CEO of the nonprofit group. "Pump choice is critical, and people with type 1 diabetes need the ability to choose the devices that work best for them."

In a news release, J&J said it "remains committed to the prevention and treatment of diabetes," and will continue to serve patients through products from its medical-device, pharmaceuticals, and consumer businesses in areas such as bariatric surgery and medicines such as Invokana (canagliflozin) and Invokamet (canagliflozin/metformin HCI), which are used to treat type 2 diabetes.

___

(c)2017 Philly.com

Visit Philly.com at www.philly.com

Distributed by Tribune Content Agency, LLC.

© Tribune Content Agency, source Regional News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDTRONIC PLC
10:18a MEDTRONIC : and Mercy Announce Data Sharing Partnership to Accelerate Medical De..
10/16 MEDTRONIC : Care Management Services and American Well Announce Strategic Partne..
10/13 MEDTRONIC : Prosthetics-Seattle (Medtronic) Pay Only DOS 09/18/17 (VA-18-919420)..
10/13 MEDTRONIC : 65-- Prosthetics-Seattle (Medtronic) Pay Only DOS 09/18/17 (VA-18-91..
10/13 65-- RFI MEDTRONIC - NX EQ RADIO FRE : Tissue Ablation Program;
10/13 MEDTRONIC : and Mercy Announce Data Sharing Partnership to Accelerate Medical De..
10/12 MEDTRONIC : Animas Corporation to Close Operations and Exit Insulin Pump Market
10/12 MEDTRONIC : to Establish Innovation Center in Chengdu
10/11 MEDTRONIC : to Establish Innovation Center in Chengdu
10/11 MEDTRONIC : to build innovation center in Chengdu
More news
News from SeekingAlpha
10/12 Wright Can't Get It Right
10/12 My Dividend Growth Portfolio - Q3 2017 Summary
10/12 The Lower Volatility Stock Portfolio For Retirees And Others
10/10 YOUR DAILY PHARMA SCOOP : MannKind Is A Trade Not An Investment; AstraZeneca's I..
10/09 First meeting of new FDA advisory committee this week
Financials ($)
Sales 2018 29 275 M
EBIT 2018 8 315 M
Net income 2018 4 638 M
Debt 2018 16 851 M
Yield 2018 2,37%
P/E ratio 2018 23,51
P/E ratio 2019 20,08
EV / Sales 2018 4,17x
EV / Sales 2019 3,94x
Capitalization 105 B
Chart MEDTRONIC PLC
Duration : Period :
Medtronic PLC Technical Analysis Chart | MDT | IE00BTN1Y115 | 4-Traders
Technical analysis trends MEDTRONIC PLC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 90,0 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Omar S. Ishrak Chairman & Chief Executive Officer
Mark Ploof Senior Vice President-Global Operations
Karen L. Parkhill Chief Financial Officer & Executive Vice President
Richard E. Kuntz Chief Scientific, Clinical & Regulatory Officer
Richard H. Anderson Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC9.60%105 292
BAXTER INTERNATIONAL41.68%34 681
ZIMMER BIOMET HOLDINGS INC15.99%24 164
C R BARD INC43.94%23 493
HOYA CORPORATION27.19%21 742
TERUMO CORP7.86%15 788